ALMR
Alamar Biosciences, Inc.
Price Chart
Latest Quote
$21.49
+0.55 (+2.63%)
Current Price
| Previous Close | $20.94 |
| Open | $20.95 |
| Day High | $22.09 |
| Day Low | $20.95 |
| Volume | 132,056 |
Stock Information
| Shares Outstanding | 69.31M |
| Total Debt | $105.55M |
| Cash Equivalents | $64.59M |
| Revenue | $87.16M |
| Net Income | $-43.48M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $1.42B |
| EPS (TTM) | $-0.65 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.70B |
| Sales | $87.16M |
| Income | $-43.48M |
| Book/sh | $-2.57 |
| Cash/sh | $0.93 |
| Employees | 222 |
Financial Ratios
| Quick Ratio | 3.50 |
| Current Ratio | 5.88 |
| Debt/Eq | 185.42 |
Returns & Margins
| Gross Margin | 57.11% |
| Operating Margin | -47.42% |
| Profit Margin | -49.89% |
Ownership
| Insider Ownership | 26.67% |
| Institutional Ownership | 28.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -29.19 |
| P/S | 16.33 |
| P/B | -8.00 |
Analyst Data
| Recommendation | none |
| Target Price | $30.00 |
Technical Indicators
| SMA20 | $21.21 |
| RSI | 44.73 |
| ATR | 1.3314 |
| Shares Float | 38.15M |
| Short Float | 3.98% |
| Short Ratio | 3.16 |
| Rel Volume | 1.26 |
Performance History
| Week | +0.49% |
| Month | -13.84% |
| YTD | -6.64% |
| 10 Years | -6.64% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $20.54 | 280,000 |
| 2026-06-04 | $21.49 | 133,300 |
| 2026-06-03 | $20.94 | 145,300 |
| 2026-06-02 | $20.80 | 57,300 |
| 2026-06-01 | $20.51 | 136,300 |
| 2026-05-29 | $20.44 | 402,200 |
| 2026-05-28 | $19.76 | 171,800 |
| 2026-05-27 | $19.12 | 211,000 |
| 2026-05-26 | $19.09 | 388,100 |
| 2026-05-22 | $20.06 | 260,200 |
| 2026-05-21 | $22.00 | 337,000 |
| 2026-05-20 | $20.16 | 197,000 |
| 2026-05-19 | $20.51 | 140,200 |
| 2026-05-18 | $20.86 | 272,500 |
| 2026-05-15 | $21.54 | 253,100 |
| 2026-05-14 | $22.51 | 225,400 |
| 2026-05-13 | $23.01 | 222,300 |
| 2026-05-12 | $22.97 | 158,700 |
| 2026-05-11 | $23.88 | 139,100 |
| 2026-05-08 | $23.96 | 304,600 |
| 2026-05-07 | $23.66 | 270,100 |
| 2026-05-06 | $23.84 | 289,600 |
About Alamar Biosciences, Inc.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Reconciled Cost Of Revenue | $32,506,000 | $16,535,000 |
| Cost Of Revenue | $32,506,000 | $16,535,000 |
| Total Revenue | $74,211,000 | $25,142,000 |
| Operating Revenue | $73,711,000 | $25,142,000 |
| Expenses | ||
| Interest Expense | $401,000 | $2,078,000 |
| Total Expenses | $105,545,000 | $74,710,000 |
| Other Income Expense | $421,000 | $-89,000 |
| Other Non Operating Income Expenses | $421,000 | $-89,000 |
| Net Non Operating Interest Income Expense | $1,759,000 | $2,597,000 |
| Interest Expense Non Operating | $401,000 | $2,078,000 |
| Operating Expense | $73,039,000 | $58,175,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-29,819,000 | $-47,073,000 |
| Net Interest Income | $1,759,000 | $2,597,000 |
| Interest Income | $2,160,000 | $4,675,000 |
| Normalized Income | $-29,819,000 | $-47,073,000 |
| Net Income From Continuing And Discontinued Operation | $-29,819,000 | $-47,073,000 |
| Total Operating Income As Reported | $-31,334,000 | $-49,568,000 |
| Net Income Common Stockholders | $-29,819,000 | $-47,073,000 |
| Net Income | $-29,819,000 | $-47,073,000 |
| Net Income Including Noncontrolling Interests | $-29,819,000 | $-47,073,000 |
| Net Income Continuous Operations | $-29,819,000 | $-47,073,000 |
| Pretax Income | $-29,154,000 | $-47,060,000 |
| Interest Income Non Operating | $2,160,000 | $4,675,000 |
| Operating Income | $-31,334,000 | $-49,568,000 |
| Gross Profit | $41,705,000 | $8,607,000 |
| Per Share | ||
| Diluted EPS | $-0.45 | $-0.71 |
| Basic EPS | $-0.45 | $-0.71 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-24,889,000 | $-41,788,000 |
| Reconciled Depreciation | $3,864,000 | $3,194,000 |
| EBITDA (Bullshit earnings) | $-24,889,000 | $-41,788,000 |
| EBIT | $-28,753,000 | $-44,982,000 |
| Diluted Average Shares | $66,521,425 | $66,521,425 |
| Basic Average Shares | $66,521,425 | $66,521,425 |
| Diluted NI Availto Com Stockholders | $-29,819,000 | $-47,073,000 |
| Tax Provision | $665,000 | $13,000 |
| Research And Development | $37,471,000 | $39,234,000 |
| Selling General And Administration | $35,568,000 | $18,941,000 |
Fetched: 2026-06-05
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-160,942,000 | $-135,455,000 |
| Total Assets | $139,992,000 | $149,511,000 |
| Total Non Current Assets | $45,287,000 | $42,814,000 |
| Other Non Current Assets | $6,671,000 | $5,673,000 |
| Goodwill And Other Intangible Assets | $1,988,000 | $2,044,000 |
| Other Intangible Assets | $1,988,000 | $2,044,000 |
| Current Assets | $94,705,000 | $106,697,000 |
| Other Current Assets | $13,468,000 | $5,609,000 |
| Inventory | $38,482,000 | $14,408,000 |
| Receivables | $12,753,000 | $7,322,000 |
| Accounts Receivable | $12,753,000 | $6,648,000 |
| Cash Cash Equivalents And Short Term Investments | $30,002,000 | $79,358,000 |
| Cash And Cash Equivalents | $30,002,000 | $26,770,000 |
| Other Receivables | - | $674,000 |
| Debt | ||
| Total Debt | $41,473,000 | $33,101,000 |
| Long Term Debt And Capital Lease Obligation | $39,374,000 | $31,190,000 |
| Long Term Debt | $9,810,000 | - |
| Current Debt And Capital Lease Obligation | $2,099,000 | $1,911,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $298,946,000 | $282,922,000 |
| Total Non Current Liabilities Net Minority Interest | $275,216,000 | $266,331,000 |
| Other Non Current Liabilities | $599,000 | - |
| Derivative Product Liabilities | $247,000 | $145,000 |
| Current Liabilities | $23,730,000 | $16,591,000 |
| Current Deferred Liabilities | $1,204,000 | $575,000 |
| Payables And Accrued Expenses | $13,571,000 | $8,683,000 |
| Payables | $5,872,000 | $6,187,000 |
| Accounts Payable | $5,872,000 | $6,187,000 |
| Equity | ||
| Common Stock Equity | $-158,954,000 | $-133,411,000 |
| Total Equity Gross Minority Interest | $-158,954,000 | $-133,411,000 |
| Stockholders Equity | $-158,954,000 | $-133,411,000 |
| Gains Losses Not Affecting Retained Earnings | $-72,000 | $149,000 |
| Other Equity Adjustments | $-72,000 | $149,000 |
| Retained Earnings | $-168,775,000 | $-138,956,000 |
| Preferred Securities Outside Stock Equity | $234,996,000 | $234,996,000 |
| Other | ||
| Ordinary Shares Number | $66,521,425 | $66,521,425 |
| Share Issued | $66,521,425 | $66,521,425 |
| Tangible Book Value | $-160,942,000 | $-135,455,000 |
| Invested Capital | $-149,144,000 | $-133,411,000 |
| Working Capital | $70,975,000 | $90,106,000 |
| Capital Lease Obligations | $31,663,000 | $33,101,000 |
| Total Capitalization | $-149,144,000 | $-133,411,000 |
| Additional Paid In Capital | $9,892,000 | $5,395,000 |
| Capital Stock | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 |
| Long Term Capital Lease Obligation | $29,564,000 | $31,190,000 |
| Current Deferred Revenue | $470,000 | $575,000 |
| Current Capital Lease Obligation | $2,099,000 | $1,911,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,856,000 | $5,422,000 |
| Current Accrued Expenses | $7,699,000 | $2,496,000 |
| Net PPE | $36,628,000 | $35,097,000 |
| Accumulated Depreciation | $-8,337,000 | $-5,557,000 |
| Gross PPE | $44,965,000 | $40,654,000 |
| Leases | $1,053,000 | $151,000 |
| Other Properties | $27,150,000 | $27,574,000 |
| Machinery Furniture Equipment | $16,762,000 | $12,929,000 |
| Properties | $0 | $0 |
| Finished Goods | $10,820,000 | $4,209,000 |
| Work In Process | $2,921,000 | $1,075,000 |
| Raw Materials | $24,741,000 | $9,124,000 |
| Other Short Term Investments | $0 | $52,588,000 |
Fetched: 2026-06-05
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-59,992,000 | $-58,602,000 |
| Operating Activities | ||
| Operating Cash Flow | $-53,608,000 | $-55,214,000 |
| Cash Flow From Continuing Operating Activities | $-53,608,000 | $-55,214,000 |
| Operating Gains Losses | $42,000 | $10,000 |
| Investing Activities | ||
| Capital Expenditure | $-6,384,000 | $-3,388,000 |
| Investing Cash Flow | $46,176,000 | $-53,933,000 |
| Cash Flow From Continuing Investing Activities | $46,176,000 | $-53,933,000 |
| Capital Expenditure Reported | $-1,011,000 | $-440,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $1,493,000 | $128,417,000 |
| Financing Cash Flow | $10,836,000 | $113,417,000 |
| Cash Flow From Continuing Financing Activities | $10,836,000 | $113,417,000 |
| Net Other Financing Charges | $-657,000 | - |
| Net Preferred Stock Issuance | $0 | $127,477,000 |
| Preferred Stock Issuance | $0 | $127,477,000 |
| Net Common Stock Issuance | $1,493,000 | $940,000 |
| Common Stock Issuance | $1,493,000 | $940,000 |
| Other | ||
| Repayment Of Debt | $0 | $-15,000,000 |
| Issuance Of Debt | $10,000,000 | $0 |
| Interest Paid Supplemental Data | $131,000 | $2,052,000 |
| End Cash Position | $34,909,000 | $31,677,000 |
| Beginning Cash Position | $31,677,000 | $27,408,000 |
| Effect Of Exchange Rate Changes | $-172,000 | $-1,000 |
| Changes In Cash | $3,404,000 | $4,270,000 |
| Net Issuance Payments Of Debt | $10,000,000 | $-15,000,000 |
| Net Short Term Debt Issuance | $10,000,000 | $0 |
| Short Term Debt Issuance | $10,000,000 | $0 |
| Net Long Term Debt Issuance | $10,000,000 | $-15,000,000 |
| Long Term Debt Payments | $0 | $-15,000,000 |
| Long Term Debt Issuance | $10,000,000 | $0 |
| Net Investment Purchase And Sale | $52,560,000 | $-50,545,000 |
| Sale Of Investment | $57,500,000 | $41,984,000 |
| Purchase Of Investment | $-4,940,000 | $-92,529,000 |
| Net PPE Purchase And Sale | $-5,373,000 | $-2,948,000 |
| Purchase Of PPE | $-5,373,000 | $-2,948,000 |
| Change In Working Capital | $-32,570,000 | $-11,989,000 |
| Change In Other Current Liabilities | $-1,918,000 | $-1,623,000 |
| Change In Other Current Assets | $-746,000 | $-675,000 |
| Change In Payables And Accrued Expense | $5,814,000 | $6,405,000 |
| Change In Accrued Expense | $6,386,000 | $3,488,000 |
| Change In Payable | $-572,000 | $2,917,000 |
| Change In Account Payable | $-572,000 | $2,917,000 |
| Change In Prepaid Assets | $-6,442,000 | $-2,246,000 |
| Change In Inventory | $-23,781,000 | $-8,753,000 |
| Change In Receivables | $-5,497,000 | $-5,097,000 |
| Changes In Account Receivables | $-5,910,000 | $-4,684,000 |
| Other Non Cash Items | $2,127,000 | $1,664,000 |
| Stock Based Compensation | $2,870,000 | $873,000 |
| Amortization Of Securities | $-122,000 | $-1,893,000 |
| Depreciation Amortization Depletion | $3,864,000 | $3,194,000 |
| Depreciation And Amortization | $3,864,000 | $3,194,000 |
| Gain Loss On Investment Securities | $102,000 | $10,000 |
| Net Foreign Currency Exchange Gain Loss | $-60,000 | $0 |
| Net Income From Continuing Operations | $-29,819,000 | $-47,073,000 |
Fetched: 2026-06-05